{
  "timestamp": "2025-11-26T16:36:54.510618",
  "summary": {
    "total_responses": 5,
    "mean_reward": -10.0,
    "median_reward": -10.0,
    "std_reward": 0.0,
    "min_reward": -10.0,
    "max_reward": -10.0,
    "rewards": [
      -10.0,
      -10.0,
      -10.0,
      -10.0,
      -10.0
    ]
  },
  "detailed_results": [
    {
      "index": 0,
      "response": "{\n  \"analysis\": \"The provided context contains extensive information about DIPG, experimental therapies, and genetic mutations, but it does not mention William Shakespeare, Hamlet, or the authorship of Hamlet. Therefore, there is no basis in the context to answer who wrote 'Hamlet'.\",\n  \"proof\": \"\",\n  \"final\": \"I cannot answer based on the provided context.\"\n}",
      "reward": -10.0,
      "context": "The experimental drug GD2 CAR T-cell therapy has shown potential in preclinical models of DIPG with ACVR1 mutation.\nUtilizing re-irradiation to deliver GSK-J4 is a novel therapeutic strategy being investigated for DIPG.\nIn pediatric diffuse midline glioma, the presence of an EZH2 inhibition is often associated with tumor regression.\nDespite initial responses, prolonged overall survival is a common challenge with AZD0156 in pontine glioma treatment.\nIn pediatric DIPG, the presence of an H3 K27M mutation is often associated with tumor regression.\nDespite initial responses, significant toxicity is a common challenge with AZD0156 in H3 K27M-mutant glioma treatment.\nThe experimental drug GD2 CAR T-cell therapy has shown potential in preclinical models of pontine glioma with EZH2 inhibition.\nUtilizing proton beam therapy to deliver GD2 CAR T-cell therapy is a novel therapeutic strategy being investigated for diffuse midline glioma.\nThe experimental drug AZD0156 has shown potential in preclinical models of DIPG with ATRX loss.\nIn pediatric DIPG, the presence of an ATRX loss is often associated with tumor regression.\nDespite initial responses, prolonged overall survival is a common challenge with panobinostat in DIPG treatment.\nAccording to a recent neuro-oncology consortium report, Despite initial responses, significant toxicity is a common challenge with GD2 CAR T-cell therapy in H3 K27M-mutant glioma treatment.\nThe experimental drug GD2 CAR T-cell therapy has shown potential in preclinical models of H3 K27M-mutant glioma with elevated GD2 expression.\nDespite initial responses, significant toxicity is a common challenge with panobinostat in H3 K27M-mutant glioma treatment.\nThe experimental drug ONC201 (dordaviprone) has shown potential in preclinical models of diffuse midline glioma with EZH2 inhibition.\nIn pediatric H3 K27M-mutant glioma, the presence of an TP53 mutation is often associated with tumor regression.\nUtilizing re-irradiation to deliver GD2 CAR T-cell therapy is a novel therapeutic strategy being investigated for diffuse midline glioma.\nIn pediatric pontine glioma, the presence of an H3 K27M mutation is often associated with significant toxicity.\nUtilizing proton beam therapy to deliver GSK-J4 is a novel therapeutic strategy being investigated for pontine glioma.\nUtilizing re-irradiation to deliver panobinostat is a novel therapeutic strategy being investigated for pontine glioma.\nDespite initial responses, radiographic improvement is a common challenge with panobinostat in H3 K27M-mutant glioma treatment.\nUtilizing convection-enhanced delivery (CED) to deliver GD2 CAR T-cell therapy is a novel therapeutic strategy being investigated for pontine glioma.\nIn pediatric H3 K27M-mutant glioma, the presence of an ACVR1 mutation is often associated with significant toxicity.\nUtilizing re-irradiation to deliver GSK-J4 is a novel therapeutic strategy being investigated for H3 K27M-mutant glioma.\nUtilizing re-irradiation to deliver ONC201 (dordaviprone) is a novel therapeutic strategy being investigated for pontine glioma.\nUtilizing intra-arterial chemotherapy to deliver GD2 CAR T-cell therapy is a novel therapeutic strategy being investigated for diffuse midline glioma.\nIn pediatric DIPG, the presence of an TP53 mutation is often associated with radiographic improvement.",
      "question": "Based on this, Who wrote 'Hamlet'?",
      "expected_answer": {
        "final": "The provided context from the neuro-oncology report does not contain the information needed to answer that question.",
        "proof": "The provided context ('Despite initial responses, significant toxicity is a common challenge with GD2 CAR T-cell therapy in H3 K27M-mutant glioma treatment.') does not contain information relevant to the user's question about 'Who wrote 'Hamlet'?'."
      }
    },
    {
      "index": 1,
      "response": "",
      "reward": -10.0,
      "context": "Utilizing intra-arterial chemotherapy to deliver ONC201 (dordaviprone) is a novel therapeutic strategy being investigated for diffuse midline glioma.\nUtilizing re-irradiation to deliver AZD0156 is a novel therapeutic strategy being investigated for pontine glioma.\nDespite initial responses, radiographic improvement is a common challenge with panobinostat in H3 K27M-mutant glioma treatment.\nDespite initial responses, prolonged overall survival is a common challenge with panobinostat in DIPG treatment.\nUtilizing proton beam therapy to deliver ONC201 (dordaviprone) is a novel therapeutic strategy being investigated for diffuse midline glioma.\nThe experimental drug AZD0156 has shown potential in preclinical models of DIPG with H3 K27M mutation.\nUtilizing re-irradiation to deliver AZD0156 is a novel therapeutic strategy being investigated for H3 K27M-mutant glioma.\nIn pediatric diffuse midline glioma, the presence of an ACVR1 mutation is often associated with radiographic improvement.\nThe presence of an TP53 mutation is a key biomarker in diffuse midline glioma. (Source A). The experimental drug ONC201 (dordaviprone) has demonstrated radiographic improvement specifically in tumors expressing the TP53 mutation. (Source B).\nIn pediatric diffuse midline glioma, the presence of an elevated GD2 expression is often associated with acquired resistance.\nUtilizing intra-arterial chemotherapy to deliver AZD0156 is a novel therapeutic strategy being investigated for pontine glioma.\nThe experimental drug GSK-J4 has shown potential in preclinical models of H3 K27M-mutant glioma with ACVR1 mutation.\nThe experimental drug AZD0156 has shown potential in preclinical models of diffuse midline glioma with H3 K27M mutation.\nDespite initial responses, prolonged overall survival is a common challenge with GSK-J4 in H3 K27M-mutant glioma treatment.\nThe experimental drug ONC201 (dordaviprone) has shown potential in preclinical models of diffuse midline glioma with ATRX loss.\nDespite initial responses, prolonged overall survival is a common challenge with GD2 CAR T-cell therapy in pontine glioma treatment.\nUtilizing proton beam therapy to deliver panobinostat is a novel therapeutic strategy being investigated for DIPG.\nIn pediatric pontine glioma, the presence of an elevated GD2 expression is often associated with significant toxicity.\nIn pediatric H3 K27M-mutant glioma, the presence of an EZH2 inhibition is often associated with prolonged overall survival.\nThe experimental drug AZD0156 has shown potential in preclinical models of pontine glioma with TP53 mutation.\nDespite initial responses, acquired resistance is a common challenge with ONC201 (dordaviprone) in DIPG treatment.\nDespite initial responses, prolonged overall survival is a common challenge with GSK-J4 in DIPG treatment.\nThe experimental drug panobinostat has shown potential in preclinical models of H3 K27M-mutant glioma with EZH2 inhibition.\nDespite initial responses, modest clinical benefit is a common challenge with panobinostat in diffuse midline glioma treatment.\nDespite initial responses, prolonged overall survival is a common challenge with ONC201 (dordaviprone) in DIPG treatment.\nThe experimental drug panobinostat has shown potential in preclinical models of diffuse midline glioma with ATRX loss.\nDespite initial responses, acquired resistance is a common challenge with GSK-J4 in DIPG treatment.\nThe experimental drug panobinostat has shown potential in preclinical models of DIPG with ACVR1 mutation.\nDespite initial responses, radiographic improvement is a common challenge with ONC201 (dordaviprone) in diffuse midline glioma treatment.\nUtilizing intra-arterial chemotherapy to deliver GD2 CAR T-cell therapy is a novel therapeutic strategy being investigated for diffuse midline glioma.\nThe experimental drug GD2 CAR T-cell therapy has shown potential in preclinical models of pontine glioma with elevated GD2 expression.",
      "question": "Based on the provided texts, why is ONC201 (dordaviprone) being investigated for diffuse midline glioma?",
      "expected_answer": {
        "final": "ONC201 (dordaviprone) is being investigated for diffuse midline glioma because these tumors often have the TP53 mutation, and ONC201 (dordaviprone) has shown radiographic improvement in tumors with that specific marker.",
        "proof": "[Source A]: The presence of an TP53 mutation is a key biomarker in diffuse midline glioma.\n[Source B]: The experimental drug ONC201 (dordaviprone) has demonstrated radiographic improvement specifically in tumors expressing the TP53 mutation."
      }
    },
    {
      "index": 2,
      "response": "",
      "reward": -10.0,
      "context": "Despite initial responses, tumor regression is a common challenge with panobinostat in diffuse midline glioma treatment.\nIn pediatric diffuse midline glioma, the presence of an TP53 mutation is often associated with significant toxicity.\nIn pediatric pontine glioma, the presence of an EZH2 inhibition is often associated with tumor regression.\nDespite initial responses, radiographic improvement is a common challenge with panobinostat in H3 K27M-mutant glioma treatment.\nThe experimental drug GD2 CAR T-cell therapy has shown potential in preclinical models of H3 K27M-mutant glioma with ATRX loss.\nThe presence of an H3 K27M mutation is a key biomarker in H3 K27M-mutant glioma. (Source A). The experimental drug GD2 CAR T-cell therapy has demonstrated significant toxicity specifically in tumors expressing the H3 K27M mutation. (Source B).\nUtilizing convection-enhanced delivery (CED) to deliver GD2 CAR T-cell therapy is a novel therapeutic strategy being investigated for H3 K27M-mutant glioma.\nDespite initial responses, acquired resistance is a common challenge with panobinostat in diffuse midline glioma treatment.\nUtilizing proton beam therapy to deliver AZD0156 is a novel therapeutic strategy being investigated for H3 K27M-mutant glioma.\nIn pediatric H3 K27M-mutant glioma, the presence of an EZH2 inhibition is often associated with significant toxicity.\nUtilizing convection-enhanced delivery (CED) to deliver GD2 CAR T-cell therapy is a novel therapeutic strategy being investigated for H3 K27M-mutant glioma.\nDespite initial responses, acquired resistance is a common challenge with GD2 CAR T-cell therapy in pontine glioma treatment.\nUtilizing convection-enhanced delivery (CED) to deliver panobinostat is a novel therapeutic strategy being investigated for pontine glioma.\nDespite initial responses, tumor regression is a common challenge with AZD0156 in pontine glioma treatment.\nDespite initial responses, radiographic improvement is a common challenge with panobinostat in diffuse midline glioma treatment.\nIn pediatric DIPG, the presence of an EZH2 inhibition is often associated with significant toxicity.\nThe experimental drug GSK-J4 has shown potential in preclinical models of pontine glioma with TP53 mutation.\nUtilizing intra-arterial chemotherapy to deliver GSK-J4 is a novel therapeutic strategy being investigated for H3 K27M-mutant glioma.\nUtilizing intra-arterial chemotherapy to deliver panobinostat is a novel therapeutic strategy being investigated for DIPG.\nIn pediatric H3 K27M-mutant glioma, the presence of an TP53 mutation is often associated with prolonged overall survival.\nDespite initial responses, acquired resistance is a common challenge with GD2 CAR T-cell therapy in pontine glioma treatment.\nDespite initial responses, tumor regression is a common challenge with GSK-J4 in pontine glioma treatment.\nThe experimental drug GSK-J4 has shown potential in preclinical models of pontine glioma with ACVR1 mutation.\nUtilizing re-irradiation to deliver AZD0156 is a novel therapeutic strategy being investigated for pontine glioma.\nThe experimental drug panobinostat has shown potential in preclinical models of DIPG with TP53 mutation.\nUtilizing convection-enhanced delivery (CED) to deliver ONC201 (dordaviprone) is a novel therapeutic strategy being investigated for diffuse midline glioma.\nUtilizing proton beam therapy to deliver panobinostat is a novel therapeutic strategy being investigated for pontine glioma.\nThe experimental drug AZD0156 has shown potential in preclinical models of pontine glioma with ATRX loss.\nUtilizing re-irradiation to deliver panobinostat is a novel therapeutic strategy being investigated for DIPG.",
      "question": "Based on the provided texts, why is GD2 CAR T-cell therapy being investigated for H3 K27M-mutant glioma?",
      "expected_answer": {
        "final": "GD2 CAR T-cell therapy is being investigated for H3 K27M-mutant glioma because these tumors often have the H3 K27M mutation, and GD2 CAR T-cell therapy has shown significant toxicity in tumors with that specific marker.",
        "proof": "[Source A]: The presence of an H3 K27M mutation is a key biomarker in H3 K27M-mutant glioma.\n[Source B]: The experimental drug GD2 CAR T-cell therapy has demonstrated significant toxicity specifically in tumors expressing the H3 K27M mutation."
      }
    },
    {
      "index": 3,
      "response": "{\n  \"analysis\": \"The context provides two pieces of evidence about GSK-J4 in diffuse midline glioma. A Phase I clinical trial (Source A) reported significant toxicity, which suggests limited clinical benefit and safety concerns. In contrast, a preclinical mouse study (Source B) indicated that GSK-J4 provides only modest clinical benefit. Therefore, the efficacy of GSK-J4 for diffuse midline glioma appears to be modest at best, and its clinical utility is challenged by significant toxicity",
      "reward": -10.0,
      "context": "In pediatric pontine glioma, the presence of an ATRX loss is often associated with modest clinical benefit.\nThe experimental drug AZD0156 has shown potential in preclinical models of pontine glioma with EZH2 inhibition.\nUtilizing convection-enhanced delivery (CED) to deliver AZD0156 is a novel therapeutic strategy being investigated for DIPG.\nUtilizing proton beam therapy to deliver GSK-J4 is a novel therapeutic strategy being investigated for diffuse midline glioma.\nThe experimental drug ONC201 (dordaviprone) has shown potential in preclinical models of pontine glioma with ATRX loss.\nDespite initial responses, prolonged overall survival is a common challenge with panobinostat in DIPG treatment.\nDespite initial responses, significant toxicity is a common challenge with AZD0156 in DIPG treatment.\nThe experimental drug GD2 CAR T-cell therapy has shown potential in preclinical models of DIPG with TP53 mutation.\nA Phase I clinical trial report (Source A) on GSK-J4 for recurrent diffuse midline glioma indicates significant toxicity. However, a preclinical study in mouse models (Source B) suggests that GSK-J4 leads to modest clinical benefit.\nUtilizing convection-enhanced delivery (CED) to deliver panobinostat is a novel therapeutic strategy being investigated for H3 K27M-mutant glioma.\nIn pediatric H3 K27M-mutant glioma, the presence of an ACVR1 mutation is often associated with significant toxicity.\nDespite initial responses, modest clinical benefit is a common challenge with GD2 CAR T-cell therapy in DIPG treatment.\nUtilizing intra-arterial chemotherapy to deliver GSK-J4 is a novel therapeutic strategy being investigated for DIPG.\nDespite initial responses, radiographic improvement is a common challenge with AZD0156 in H3 K27M-mutant glioma treatment.\nUtilizing convection-enhanced delivery (CED) to deliver ONC201 (dordaviprone) is a novel therapeutic strategy being investigated for pontine glioma.\nIn pediatric diffuse midline glioma, the presence of an TP53 mutation is often associated with prolonged overall survival.\nUtilizing re-irradiation to deliver panobinostat is a novel therapeutic strategy being investigated for diffuse midline glioma.\nUtilizing re-irradiation to deliver ONC201 (dordaviprone) is a novel therapeutic strategy being investigated for pontine glioma.\nUtilizing proton beam therapy to deliver panobinostat is a novel therapeutic strategy being investigated for diffuse midline glioma.\nIn pediatric diffuse midline glioma, the presence of an ACVR1 mutation is often associated with acquired resistance.\nThe experimental drug GD2 CAR T-cell therapy has shown potential in preclinical models of diffuse midline glioma with ATRX loss.\nIn pediatric DIPG, the presence of an EZH2 inhibition is often associated with prolonged overall survival.\nThe experimental drug panobinostat has shown potential in preclinical models of diffuse midline glioma with ATRX loss.\nIn pediatric pontine glioma, the presence of an EZH2 inhibition is often associated with acquired resistance.\nDespite initial responses, modest clinical benefit is a common challenge with GD2 CAR T-cell therapy in diffuse midline glioma treatment.\nIn pediatric H3 K27M-mutant glioma, the presence of an ATRX loss is often associated with significant toxicity.\nIn pediatric DIPG, the presence of an elevated GD2 expression is often associated with tumor regression.\nIn pediatric H3 K27M-mutant glioma, the presence of an ACVR1 mutation is often associated with significant toxicity.",
      "question": "Based only on the provided texts, what is the efficacy of GSK-J4 for diffuse midline glioma?",
      "expected_answer": {
        "final": "The provided sources present conflicting information. Source A suggests significant toxicity, while Source B indicates modest clinical benefit.",
        "proof": "[Source A]: A Phase I clinical trial report (Source A) on GSK-J4 for recurrent diffuse midline glioma indicates significant toxicity.\n[Source B]: However, a preclinical study in mouse models (Source B) suggests that GSK-J4 leads to modest clinical benefit."
      }
    },
    {
      "index": 4,
      "response": "{\n  \"analysis\": \"The context indicates that AZD0156 has demonstrated preclinical efficacy in H3 K27M\u2011mutant glioma, especially those harboring an ACVR1 mutation. Because of this promising activity, researchers are exploring novel",
      "reward": -10.0,
      "context": "In pediatric H3 K27M-mutant glioma, the presence of an EZH2 inhibition is often associated with modest clinical benefit.\nUtilizing intra-arterial chemotherapy to deliver AZD0156 is a novel therapeutic strategy being investigated for H3 K27M-mutant glioma.\nIn pediatric DIPG, the presence of an TP53 mutation is often associated with significant toxicity.\nIn pediatric H3 K27M-mutant glioma, the presence of an H3 K27M mutation is often associated with acquired resistance.\nThe experimental drug AZD0156 has shown potential in preclinical models of H3 K27M-mutant glioma with ACVR1 mutation.\nIn pediatric diffuse midline glioma, the presence of an H3 K27M mutation is often associated with modest clinical benefit.\nThe experimental drug GSK-J4 has shown potential in preclinical models of DIPG with ATRX loss.\nDespite initial responses, significant toxicity is a common challenge with GD2 CAR T-cell therapy in H3 K27M-mutant glioma treatment.\nThe presence of an TP53 mutation is a key biomarker in diffuse midline glioma. (Source A). The experimental drug AZD0156 has demonstrated acquired resistance specifically in tumors expressing the TP53 mutation. (Source B).\nDespite initial responses, tumor regression is a common challenge with panobinostat in DIPG treatment.\nUtilizing proton beam therapy to deliver panobinostat is a novel therapeutic strategy being investigated for diffuse midline glioma.\nIn pediatric pontine glioma, the presence of an H3 K27M mutation is often associated with acquired resistance.\nThe experimental drug GSK-J4 has shown potential in preclinical models of H3 K27M-mutant glioma with EZH2 inhibition.\nIn pediatric diffuse midline glioma, the presence of an ATRX loss is often associated with modest clinical benefit.\nThe experimental drug GSK-J4 has shown potential in preclinical models of H3 K27M-mutant glioma with TP53 mutation.\nThe experimental drug GD2 CAR T-cell therapy has shown potential in preclinical models of H3 K27M-mutant glioma with elevated GD2 expression.\nThe experimental drug ONC201 (dordaviprone) has shown potential in preclinical models of pontine glioma with EZH2 inhibition.\nIn pediatric DIPG, the presence of an H3 K27M mutation is often associated with acquired resistance.\nDespite initial responses, radiographic improvement is a common challenge with panobinostat in diffuse midline glioma treatment.\nUtilizing convection-enhanced delivery (CED) to deliver GSK-J4 is a novel therapeutic strategy being investigated for diffuse midline glioma.\nThe experimental drug GSK-J4 has shown potential in preclinical models of H3 K27M-mutant glioma with EZH2 inhibition.\nUtilizing proton beam therapy to deliver AZD0156 is a novel therapeutic strategy being investigated for diffuse midline glioma.\nThe experimental drug GD2 CAR T-cell therapy has shown potential in preclinical models of DIPG with ACVR1 mutation.\nUtilizing re-irradiation to deliver AZD0156 is a novel therapeutic strategy being investigated for diffuse midline glioma.\nThe experimental drug GSK-J4 has shown potential in preclinical models of pontine glioma with ACVR1 mutation.\nIn pediatric DIPG, the presence of an TP53 mutation is often associated with radiographic improvement.\nIn pediatric pontine glioma, the presence of an ACVR1 mutation is often associated with acquired resistance.",
      "question": "Based on the provided texts, why is AZD0156 being investigated for diffuse midline glioma?",
      "expected_answer": {
        "final": "AZD0156 is being investigated for diffuse midline glioma because these tumors often have the TP53 mutation, and AZD0156 has shown acquired resistance in tumors with that specific marker.",
        "proof": "[Source A]: The presence of an TP53 mutation is a key biomarker in diffuse midline glioma.\n[Source B]: The experimental drug AZD0156 has demonstrated acquired resistance specifically in tumors expressing the TP53 mutation."
      }
    }
  ]
}